CAR-T therapy moving to first-line in multiple myeloma: latest updates from the 2025 ASH annual meeting.

Multiple myeloma is a challenging type of blood cancer that often returns after initial treatments. For years, doctors have used a revolutionary approach called CAR-T therapy as a last resort. This treatment involves collecting a patient's own immune cells and genetically reprogramming them to hunt down and destroy cancer cells. Now, new data reveals that using CAR-T therapies much earlier could dramatically change how this disease is treated, showing powerful effectiveness for both newly diagnosed patients and those whose cancer has returned or resisted prior drugs.

Recent clinical trials have produced striking results for patients receiving CAR-T therapy right after their diagnosis. In frontline studies, researchers reported an unprecedented 100 percent overall response rate, meaning every single patient saw their cancer shrink or disappear. Additionally, 88 to 92 percent of these patients were still alive two and a half years later. The treatment also excelled in patients who had already exhausted other options. In a major trial known as CARTITUDE-4, 71 percent of patients given CAR-T therapy lived for two and a half years without their disease getting worse. By comparison, only 43.2 percent of patients on standard treatments achieved that same milestone.

The therapy is also proving highly effective for older adults, a group that can sometimes struggle with harsh cancer treatments. In a trial focusing on patients aged 70 or older, a specific CAR-T treatment called idecabtagene vicleucel led to an 81.6 percent response rate, which vastly outperformed the 48.1 percent response rate seen with standard care. However, scientists caution that we are still in the early days of understanding the ultimate survival benefits for this older group. The median overall survival time has not yet been reached for these patients, indicating that longer follow-up observations are needed.